PMLiVE22h
EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
Medscape3h
European Commission Approves Nemolizumab for Atopic Dermatitis and Prurigo Nodularis
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
The Pharma Letter19h
Galderma doubles up on Nemluvio approvals
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...
Galderma's Nemluvio® (Nemolizumab) Granted Marketing Authorization In The United Kingdom And Switzerland For Moderate-To...
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...
FiercePharma23h
Regulatory tracker: Europe approves CSL's HAE drug, Arcturus-partnered COVID vaccine
in patients with moderate-to-severe atopic dermatitis and adults with prurigo nodularis, respectively," Galderma said in a Friday press release. The drug is also approved in the U.S. and is under ...
openaccessgovernment23h
Nenolizumab has recently been approved for two chronic skin conditions
A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two ...